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Biotin-responsive basal ganglia disease (BBGD) is a recessive disorder with childhood onset that presents as a
subacute encephalopathy, with confusion, dysarthria, and dysphagia, and that progresses to severe cogwheel rigidity,
dystonia, quadriparesis, and eventual death, if left untreated. BBGD symptoms disappear within a few days with
the administration of high doses of biotin (5–10 mg/kg/d). On brain magnetic resonance imaging examination,
patients display central bilateral necrosis in the head of the caudate, with complete or partial involvement of the
putamen. All patients diagnosed to date are of Saudi, Syrian, or Yemeni ancestry, and all have consanguineous
parents. Using linkage analysis in four families, we mapped the genetic defect near marker D2S2158 in 2q36.3
( ; ) to a minimum candidate region (∼2 Mb) between D2S2354 and D2S1256, on the basis ofLODp 5.9 vp 0.0
complete homozygosity. In this segment, each family displayed one of two different missense mutations that altered
the coding sequence of SLC19A3, the gene for a transporter related to the reduced-folate (encoded by SLC19A1)
and thiamin (encoded by SLC19A2) transporters.
Introduction
Biotin-responsive basal ganglia disease (BBGD [MIM
607483]) was first described in 1998 in a number of
families in Saudi Arabia (Ozand et al. 1998). Patients
presented in childhood with a subacute encephalopathic
picture of undefined origin, including confusion, vom-
iting, and a vague history of febrile illness. They pro-
gressed to acute encephalopathy, with sudden loss of
developmental milestones; inability to swallow; loss of
speech (or slurred speech); loss of motor function, with
development of quadriparesis or quadriplegia; and sei-
zures. Left untreated, the disorder results in a chronic
or slowly progressive encephalopathy, with an akinetic
mute state, permanent loss of speech and comprehen-
sion, and eventual death. Magnetic resonance imaging
(MRI) examination of patients with BBGD revealed spe-
cific bilateral necrosis in the head of the caudate nucleus
and in the putamen. However, results of tests to uncover
evidence of infection, storage or mitochondrial diseases,
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or toxicological damage were all negative. Since all af-
fected individuals had consanguineous parents, it was
concluded that BBGD is likely due to a recessive genetic
defect. Fortunately, administration of high doses of bi-
otin (5–10 mg/kg/d) early in the disorder was found to
eliminate the symptoms of BBGD within a few days,
with no recurrence unless biotin treatment was discon-
tinued. In the latter circumstance, symptoms returned
within a month. Treatment later in the disorder left re-
sidual paraparesis, mild mental retardation, or dystonia.
Even when biotin administration resolved the clinical
symptoms of BBGD, the abnormal MRI findings re-
mained but showed no further progression.
Biotin is essential for the activity of a number of criti-
cal carboxylases, including propionyl coenzyme A (CoA),
acetyl CoA, 3-methylcrotonyl CoA, and pyruvate car-
boxylases (Moss and Lane 1971). These are converted
from apoenzymes to active holoenzymes by transfer of
biotin from holocarboxylase synthetase. Specific carbox-
ylase deficiencies have been described that are due to
mutations in the corresponding structural genes. Muta-
tion in the holocarboxylase synthetase gene leads to mul-
tiple carboxylase deficiency (Suzuki et al. 1994; Aoki et
al. 1995; Dupuis et al. 1996; Narisawa et al. 1996),
which may, in some cases, be biotin responsive (Wolf and
Feldman 1982). Since biotin is not synthesized de novo
in humans, multiple carboxylase deficiency may also re-
sult from mutation in biotinidase (Pomponio et al. 1995),
which is essential for recycling endogenous biotin. The
patients with BBGD did not display deficiency of any of
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these enzymes, indicating that their genetic defect lay in
some additional component of biotin metabolism. We
have used linkage mapping and positional cloning to
identify mutations in the transporter gene SLC19A3 as
the cause of BBGD in four families.
Material and Methods
Families with BBGD
Four families with seven affected members are shown
in figure 1. After institutional review board approval,
informed consent to participate and blood samples were
obtained from patients and family members; standard
methods were used for extraction of DNA. Families 11,
30, and 44 are of Saudi origin; these families each in-
volve a first-cousin mating, and they each comprise af-
fected individuals described in the study by Ozand et al.
(1998) (patients 1 [patient 1103 in the present study],
2 [1102], 3 [4407], 4 [4408], and 7 [3003]). Related
kindreds 12 and 14 are of Yemeni origin. Affected in-
dividual 1403 was described as “patient 6” in the study
by Ozand et al. (1998). Affected individual 1203 is a
previously undescribed affected family member with fea-
tures of BBGD; this individual has an affected sibling
not available for the present study.
Genotyping
PCR was performed in a total volume of 7.5 ml, with
30 ng/ml of genomic DNA, 0.1–1.0 ml (of a 5-mM con-
centration) of each dye-labeled primer pair (PerkinElmer/
Applied Biosystems and Research Genetics), 0.06 ml (of
a 5-U/ml concentration) AmpliTaq Gold DNA poly-
merase (PerkinElmer/Applied Biosystems), 0.75 ml 10#
GeneAmp PCR buffer II (PerkinElmer/Applied Biosys-
tems), 0.75 ml GeneAmp dNTP mix (2.5 mM [Perkin-
Elmer]), 0.75 ml MgCl2 (25 mM), and sufficient dH2O
to bring the final volume to 7.5 ml. PCR was performed
in the MJ Research DNA Engine tetrad with the follow-
ing conditions: initial denaturation at 95C for 12 min;
10 cycles at 94C for 30 s, 58C for 30 s, and 72C for
60 s; 25 cycles at 89C for 30 s, 55C for 30 s, and 72C
for 60 s; and 1 cycle at 72C for 40 min. Analysis of
marker D2S1256 used reagents as stated above, except
for the final MgCl2 concentration, which was 1.0 mM,
not 2.5 mM. The PCR conditions were also different:
initial denaturation at 95C for 15 min; 35 cycles at 94C
for 30 s, 60C for 30 s, and 72C for 45 s; and 1 cycle
at 72C for 10 min. PCR products were run on a 4.5%
acrylamide gel (4.5% AutoPAGE Plus [Sigma]) on the
ABI 377XL DNA Sequencer (PerkinElmer/Applied Bio-
systems) for 2 h, with a size standard (GS350 TAMRA
or GS500 TAMRA [PerkinElmer/Applied Biosystems])
run in each lane to ensure lane-to-lane and gel-to-gel
size-calling consistency. The data from the gels were an-
alyzed with ABI GeneScan, version 3.1, and Genotyper,
version 2.1, software. The genome scan used 302 highly
polymorphic di-, tri-, and tetranucleotide repeat micro-
satellite markers from the ABI Linkage Mapping Set,
versions 1 and 2 (PerkinElmer), and from the Weber
Human Screening Set, version 9 (Research Genetics). Af-
ter 2q36-37 was implicated in the genome scan, we chose
additional markers in this vicinity using the Human Ge-
nome Database and the UCSC Genome Browser. Se-
quences for primers used for markers in figure 1 are listed
in table 1. Allele sizes were related to previous typing
on the CEPH panel by regenotyping CEPH individual
133101 (Fondation Jean Dausset CEPH Web Server).
Alleles were numbered in figure 1, consistent with the
allele designations given in the Human Genome Data-
base, except for the following alleles: alleles 1–9 of
D2S1344 were 280–304 bp, differing by 3 bp; alleles
1–11 of D2S1256 were 285–325 bp, differing by 4 bp;
and alleles 1 and 2 of D2S260 were 269 bp and 267
bp, respectively.
Two microsatellite markers, D19S596 and D19S867
(table 1), flanking the 1.2-Mb critical region in 19q13
that was defined for infantile bilateral striatal necrosis,
were specifically genotyped to exclude this genomic seg-
ment. PCR cycling conditions were the same as for ge-
nome scan markers, except that the second set of cycles
was performed 21 times and 23 times, respectively, for
D19S596 and D19S867. These products were analyzed
on Applied Biosystems 3730xl DNA Analyzer, with size
standard GS500 LIZ. The data were analyzed with
GeneMapper, version 3.5 (Applied Biosystems).
Statistical Analysis
Two-point LOD scores between the disease locus and
the individual markers in our screening set were calcu-
lated using the MLINK program of the FASTLINK 3.0P
software package (Lathrop and Lalouel 1984; Lathrop
et al. 1984, 1986; Cottingham et al. 1993; Schaffer et
al. 1994; Schaffer 1996). Haplotypes were constructed
manually through visual inspection of the markers under
consideration. Fine mapping of the markers in our linked
region was accomplished by consulting known linkage
and physical maps.
Mutation Scanning
From patient genomic DNA, we amplified coding ex-
ons of SLC19A3; three exons of a neighboring hypothet-
ical gene, DKFZp547H025 (GenBank accession number
NM_020161); and two other related sequences, named
“alt3” and “alt4” (see the “Results” section and fig. 2),
and, with primers located in flanking intron and UTR
sequences, we performed standard 30-ml PCR (in 10 mM
Tris [pH 8.9], 50 mM KCl, 1.5–2.5 mM MgCl2, 10 pmol
of each primer, and 200 mM of each dNTP, including 50–
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Table 1
Primers Sequences Used for Markers on
Chromosomes 2 and 19
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1 Homozygosity mapping and 2q haplotypes in four consanguineous families with BBGD. Blackened symbols indicate patients;
unblackened symbols indicate unaffected individuals. Marker alleles, numbered as described in the “Material and Methods” section, are given
for seven affected individuals and eight parents within four families with BBGD. Boxes highlight regions of complete homozygosity in affected
individuals, indicating disease-chromosome haplotypes. Borders of the minimum candidate interval are denoted by the connected arrows.
Genotypes that were not determined are shown by square brackets. Not shown, for confidentiality, are seven unaffected siblings in three of the
families who were genotyped and included in the LOD score calculations. None of these samples showed homozygosity for the candidate region.
On the basis of the results of mutation analysis, the first three families (11, 20, and 44), all of which involve first-cousin matings, likely share
a common ancestor, with the difference in the allele for D2S1344 in family 44 likely being due to a change in the microsatellite marker repeat.
100 ng DNA and 1 U Taq polymerase [Invitrogen]). The
oligonucleotide primers were designed using Primer3 and
are available on request. The PCR products were assessed
by SSCP analysis; when an abnormal band shift was ob-
served, the sample was analyzed by direct sequencing by
using the BigDye Terminator Cycle Sequencing Kit (Ap-
plied Biosystems) on an ABI 377XL DNA Sequencer
(PerkinElmer). Screening of controls was performed by
PCR-SSCP analysis of the SLC19A3 68GrT/G23V mu-
tation: the 219-bp exon 2 product was amplified with
primers 5′-TCAGCCATGGATTGTTACAGA-3′ and 5′-
TCCTTGTTCAAGTCCCATAAAA-3′ for 30 cycles at
94C for 45 s, 58C for 45 s, and 72C for 1 min and a
final 10-min extension at 72C. The PCR product was
labeled by incorporation of [32P]-dGTP, was displayed on
8% nondenaturing polyacrylamide gels containing 10%
glycerol, and was then detected by autoradiography with
the use of XAR film (Kodak). Screening of controls was
performed by PCR-RFLP analysis of the SLC19A3 exon
5 1264ArG/T422A mutation: a 291-bp PCR product
was amplified with primers 5′-CCCTGTGGCCAATAT-
GTTCT-3′ and 5′-TTGCTTGTTGTAAGGTTGAGAAA-
3′ for 30 cycles at 94C for 45 s, 57C for 45 s, and 72C
Zeng et al.: Mutations in SLC19A3 Cause BBGD 19
Figure 2 SLC19A3 genomic region, gene structure, and BBGD point mutations. Locations of the microsatellite markers used for the
linkage study of the 2q33.3-2q37.1 region and the corresponding gene region for SLC19A3 and DKFZp547H025 are shown. The human
SLC19A3 gene is located in 2q36.3, spans 32.91 kb of genomic DNA, and consists of seven exons with a start codon in exon 2 and a TAA
stop codon in exon 6. The SLC19A3 cDNA includes a predicted 1,488-bp ORF encoding a 496-aa protein of 55.6 kDa molecular weight. One
mutation, 68 GrT, was identified in exon 2, and another mutation, 1264 ArG, was found in exon 5. Sequences alt3, alt4, and alt5 were
detected by TBLASTN search (see the BLAST Web site) and were found to be similar to SLC19A3 exons 3, 4, and 5, respectively. The nearby
hypothetical protein DKFZp547H025, which is based on a sequenced cDNA, contains three exons (alt5, along with sequences designated “alt6′”
and “alt7′,” which are unrelated to SLC19A3), with start and stop codons indicated by arrows. Nine novel SNPs were identified in the 5′ UTR,
alt3, alt6′, and alt7′ in SLC19A3 and DKFZp547H025; the SNPs were submitted to dbSNP and were assigned accession numbers 32476166–
32476174.
for 1 min and a final 10-min extension at 72C. The PCR
product was digested with BspHI to produce fragments
of 170 bp and 121 bp (wild type) and 291 bp (mutant)
and was resolved by electrophoresis on 2% agarose gels
(Invitrogen). White control chromosomes were from 162
unrelated grandparents or parents from the extended
CEPH pedigrees (Fondation Jean Dausset CEPH Web
Server). Arab control chromosomes were from the Coriell
Cell Repositories (two panels of 10 individuals each [cat-
alog IDs HD05 and HD27]) and from 42 unrelated mem-
bers of other Arab disease pedigrees collected for map-
ping/polymorphism studies.
Hydrophobicity Predictions
Hydrophobicity plots in figure 3 were determined us-
ing HMMTOP 2.0 (Tusnady and Simon 1998, 2001).
SLC19A3 (National Center for Biotechnology Infor-
mation [NCBI] Entrez Protein accession number
NP_079519) was submitted for analysis.
Results
Genome Scan
For our initial genome scan, we genotyped 12 individ-
uals, including 6 affected subjects, from four families with
302 markers (fig. 1 [excluding family 12]). On the basis
of initial positive LOD scores on the long arm of chro-
mosome 2, we added additional markers to saturate this
region, genotyping all 22 available samples: the 12 orig-
inal individuals, 3 members of family 12, and 7 unaffected
siblings in these families (not shown, for confidentiality).
Marker D2S2158 demonstrated significant linkage, with
a maximum LOD score of 5.9 at (table 2). Invp 0.0
each family, the affected individuals were homozygous for
the region surrounding D2S2158, consistent with the
known consanguinity and recessive inheritance pattern
(fig. 1). The minimum region of complete homozygosity
was between D2S2354 and D2S1256, a segment of ∼2
Mb. The families did not share identical haplotypes across
the entire minimum candidate region, indicating either
that more than one founder mutation was represented
or that a single-founder defect could be further localized
by examining regions of identity in all seven affected
individuals.
Analysis of the Candidate Region
We examined the region for known gene candidates
using the UCSC Genome Browser, as well as using 20-kb
chunks of genomic BAC sequence in BLASTX searches
(see the BLAST Web site) of GenBank, to identify addi-
tional conserved sequences. The candidate region con-
tained genes for the insulin-receptor substrate (IRS1), col-
lagens 4A3 and 4A4 (COL4A3 and COL4A4), a nu-
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Figure 3 Schematic model of the reduced-folate transporter family. SLC19A3 encodes a predicted protein containing 12 putative trans-
membrane domains. The relative positions of the mutations identified in SLC19A3 in patients with BBGD and of the missense and nonsense
mutations in SLC19A2, reported in patients with Rogers syndrome, are shown (Diaz et al. 1999; Labay et al. 1999; Raz et al. 2000; Scharfe
et al. 2000; Lagarde et al. 2004). The positions of mutations in SLC19A2 were assigned in accordance with hydrophobicity plots that were
determined by HMMTOP 2.0 (Tusnady and Simon 1998, 2001). SLC19A2 and SLC19A3 (NCBI accession numbers NP_008927 andNP_079519)
were used for analysis.
cleoporin family member (HRB), chemokine ligand 20
(CCL20), several anonymous cDNAs, and SLC19A3. We
first focused on the latter, since it is related to THTR-1
(encoded by SLC19A2), the high-affinity transporter for
thiamin, another water-soluble vitamin. Mutations in
SLC19A2 underlie thiamin-responsive megaloblastic ane-
mia (or “Rogers syndrome”) (Diaz et al. 1999; Fleming
et al. 1999; Labay et al. 1999).
SLC19A3 is predicted to comprise seven exons span-
ning 32.9 kb in 2q36.3, with the coding sequence con-
fined to exons 2–6 (fig. 2). To ensure that we identified
all SLC19A3-related potential coding sequences in the
vicinity, we used the THTR-1 protein sequence and the
predicted SLC19A3 coding sequence to search the can-
didate region with TBLASTN (see the BLAST Web site).
This search identified another set of related sequences,
which begin ∼40 kb 3′ to the gene and correspond to
sequences related to exons 3, 4, and 5; we designated
these sequences as “alt3,” “alt4,” and “alt5,” respec-
tively. The latter two represent ORFs encoding amino
acids that are 68% identical to those encoded by the
equivalent segment of SLC19A3. However, alt3 predicts
71% identity but has two separate stop codons that
interrupt the ORF. No reported human ESTs connect
alt3, alt4, and alt5 in a cDNA. However, the cDNA
DKFZp547H025 has been reported to encode a hypo-
thetical protein of 140 aa that begins from the ORF of
alt5 and continues into two additional exons with ORFs
unrelated to SLC19A3. We designated these putative
coding exons “alt6′” and “alt7′.” Since SLC19A3 and
the other potential exons are all in the same orientation,
it is conceivable that alternative splicing could produce
a hybrid transcript. Consequently, to search for the
BBGD defect, we performed mutation scanning of exons
1–6 of SLC19A3, as well as alt3, alt4, alt5, alt6′, and
alt7′.
Mutations in SLC19A3
Two putative mutations were identified in the four
families, and both of these mutations predicted missense
changes in the protein structure, as shown in figure 4.
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Table 2
LOD Scores for Linkage of BBGD to 2q36-37
MARKER
LOCATIONa
(Mb)
LOD AT vp
0 .01 .05 .1 .2 .3 .4
D2S325 208.096  .06 .85 .93 .62 .28 .08
D2S164 217.786 4.43 4.30 3.78 3.15 1.98 1.03 .38
D2S126 221.843 1.47 1.88 2.08 1.89 1.28 .67 .22
D2S266 225.111 .89 2.20 2.38 2.08 1.30 .64 .20
D2S2204 226.302 1.01 .99 1.85 1.91 1.48 .88 .36
D2S2354 227.175 3.29 3.66 3.68 3.28 2.24 1.25 .49
D2S2389 227.372 3.52 3.42 3.03 2.55 1.65 .91 .36
D2S1349 227.636 4.04 3.91 3.43 2.85 1.77 .90 .31
D2S159 227.649 4.20 4.08 3.62 3.04 1.97 1.07 .41
D2S2158 227.886 5.90 5.74 5.10 4.30 2.76 1.43 .48
D2S1344 227.912 4.94 4.80 4.27 3.60 2.34 1.26 .47
D2S401 228.084 5.66 5.50 4.86 4.06 2.55 1.29 .42
D2S439 229.006 4.39 4.26 3.75 3.13 2.00 1.06 .40
D2S1256 229.241 1.36 2.84 2.98 2.62 1.69 .88 .33
D2S260 230.090 1.78 .22 .24 .30 .20 .11 .04
D2S427 232.032 1.06 1.59 1.83 1.67 1.13 .58 .17
D2S206 233.534  .23 1.17 1.29 1.00 .58 .20
NOTE.—The peak LOD score is shown in bold italics.
a Marker location is based on the May 2004 human genome as-
sembly (UCSC Genome Browser).
The mutation in exon 2 was found in two patients (1203
and 1403) from a Yemeni family. Sequence analysis dis-
closed a homozygous GrT change at nucleotide 68,
which is predicted to alter a highly conserved glycine
at codon 23 to valine (c.68GrT; p.G23V) (fig. 2). An
equivalent glycine residue is present at this position in
mouse Slc19a3 and in both SLC19A2 and SLC19A1,
the two other members of this transporter family in
humans. This putative mutation is predicted to alter the
first transmembrane domain (fig. 3) of the SLC19A3
protein.
In the three other families, all of Saudi origin, we
identified an ArG missense mutation at nucleotide po-
sition 1264 in exon 5, that alters a BspHI restriction site
(fig. 4). This sequence change predicts a substitution of
the threonine at codon 422 of the SLC19A3 protein with
alanine (c.1264ArG, p.T422A) (fig. 2). The equivalent
threonine is also present in the penultimate transmem-
brane domain of the SLC19A1- and SLC19A2-encoded
proteins (fig. 3).
BLASTP analysis (see the BLAST Web site) of Dro-
sophila melanogaster and Caenorhabditis elegans pro-
teins with any of the human SLC19A1, SLC19A2, or
SLC19A3 proteins detects three related genes in each
species: CG6574, CG14694, and CG17036 in D. me-
lanogaster and 5D352, 5L621, and 5I82 in C. elegans.
These appear to be the only three members of the re-
duced-folate carrier transporter family in each organism,
and they are comparable to the three genes found in
mammals. However, since the transporters show greater
sequence identity within a species than across species, it
is not possible to conclusively assign an orthologue for
each of the human tranporters by sequence comparison.
For example, the SLC19A3 protein shows 33%, 33%,
and 35% identity with the three Drosophila proteins,
respectively, whereas the SLC19A2 protein shows 35%,
34%, and 34% identity with these same proteins. In-
terestingly, however, all three members of this gene fam-
ily, in both D. melanogaster and C. elegans, display con-
served glycine and threonine residues at positions com-
parable to the sites in SLC19A3 that are altered in the
families with BBGD (fig. 4).
To establish that these two alterations do not represent
benign polymorphisms, we examined 364 chromosomes
from unrelated whites in the extended CEPH collection
(Fondation Jean Dausset CEPH Web Server) and 124
chromosomes from unrelated individuals of Arab an-
cestry. None of these 488 control chromosomes pos-
sessed either alteration, arguing strongly that these mis-
sense alterations cause BBGD in these families. Un-
fortunately, since we do not have access to cell lines
from these subjects, we have not been able to determine
whether these mutations have any effect on SLC19A3
mRNA splicing in addition to their direct effect on the
protein sequence.
Discussion
SLC19A1, SLC19A2, and SLC19A3 are genes on chro-
mosomes 21q22.3, 1q24.2, and 2q36.3, respectively, en-
coding closely related proteins, termed the “reduced-fo-
late carrier family of transporters” on the basis of the
function of the SLC19A1 protein. The SLC19A2 protein
is a thiamin transporter that is defective in thiamin-re-
sponsive megaloblastic anemia (Rogers syndrome) (Diaz
et al. 1999; Fleming et al. 1999; Labay et al. 1999). The
SLC19A3 protein shares 39% identity and 56% simi-
larity with SLC19A1 and 48% identity and 64% sim-
ilarity with SLC19A2, including a single reduced-folate
carrier–related domain (aa 11–439) (Eudy et al. 2000).
Hydrophobicity analysis of all three proteins reveals a
predicted topology with 12 putative transmembrane do-
mains (fig. 3), which is consistent with a transporter
function. Northern blot and RT-PCR analyses have
showed the presence of 3.5-, 2.6-, and 2.0-kb SLC19A3
transcripts in many tissues, including brain, but with
greatest abundance in placenta, kidney, and liver. Inter-
estingly, in the mouse, a single Slc19a3 mRNA species
is seen and is relatively more abundant in the mouse
brain than has been reported for humans (Eudy et al.
2000). Our RT-PCR analysis of the SLC19A3 transcript
indicates that both exon 2 and exon 5 are expressed in
the transcript in both brain and peripheral tissues (data
not shown), suggesting that the brain-specific pathology
of BBGD is not due to alternative splicing in peripheral
tissues and that the differences in mRNA size detected
by northern blot are not due to differences in the coding
region. Refined expression studies in human intestinal
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Figure 4 SLC19A3 point mutations at sites conserved in the reduced-folate transporter family. Sequence chromatograms of the two
missense mutations and the corresponding wild-type alleles are shown in the upper panel. These mutations altered glycine (“Mutation 1”) and
threonine (“Mutation 2”) residues at codon 23 and codon 422, respectively, that are highly conserved in related transporters in humans, mouse,
and lower organisms (lower panel).
epithelial cells have shown SLC19A3 protein to be ex-
pressed at the brush-border membrane but not at the
basolateral membrane (Said et al. 2004), consistent with
a transporter function.
Our detection—in four families with BBGD, repre-
senting two different disease haplotypes—of two dif-
ferent missense changes that segregate with the disorder
but are not found on 488 control chromosomes impli-
cates SLC19A3 as the disease gene. Furthermore, these
mutations alter amino acid residues that are identical
in all of the similar transporters in humans, mouse, and
lower organisms, suggesting a strong functional pres-
sure for evolutionary conservation. The c.68GrT mu-
tation (p.G23V), found in a family of Yemeni origin,
substitutes a hydrophobic valine residue for a more flex-
ible glycine residue in the first transmembrane domain
(fig. 3). A missense mutation that changes glycine to
aspartic acid at codon 172 of SLC19A2 has also been
reported in patients with Rogers syndrome (Labay et
al. 1999; Raz et al. 2000), and two recent studies
showed that the mutant protein failed in normal-cell
targeting to the plasma membrane, with consequent loss
of the thiamin transporter activity (Balamurugan and
Said 2002; Baron et al. 2002). Indeed, the SLC19A3
G23V mutations and the clustering of Rogers syndrome
mutations in exon 2 of SLC19A2 support the view that
this exon encodes a region that is critical for successful
transport function (Diaz et al. 1999; Fleming et al.
1999; Labay et al. 1999; Raz et al. 2000; Scharfe et al.
2000; Gritli et al. 2001; Lagarde et al. 2004). The other
BBGD mutation, c.1264ArG, found in three families
of Saudi origin, also alters a transmembrane domain,
Zeng et al.: Mutations in SLC19A3 Cause BBGD 23
substituting an alanine residue for the hydrophilic thre-
onine at position 422 (p.T422A). Again, the extreme
evolutionary conservation of this threonine residue sug-
gests that it is critical for SLC19A3 function.
Since the symptoms of BBGD may be reversed by high
doses of biotin therapy, it is reasonable to suspect that
SLC19A3 may act normally as a biotin transporter. Hu-
mans lack the ability to synthesize biotin and therefore
depend entirely on dietary sources (Combs 1992). Bio-
tinidase can recycle endogenous biotin so that most of
the biotin can be preserved in the body, but biotinidase
activity is low in human brain and central spinal fluid,
restricting the recycling of biotin in the CNS (Suchy et
al. 1985; Fois et al. 1986). Normal carboxylase and
biotinidase values in patients with BBGD are consistent
with the disorder being caused by a defect in the biotin
transporter system, possibly across cerebral capillaries
at the blood-brain barrier or, alternatively, in the neu-
ronal cells themselves (Ozand et al. 1998). The caudate
neurodegeneration evident in patients with BBGD sug-
gests that striatal neurons may be particularly suscep-
tible to a lack of adequate biotin. The high dosage of
biotin used to treat BBGD may then act simply by in-
creasing passive diffusion, making sufficient biotin avail-
able to the caudate nucleus (Spector and Mock 1987).
Recently, investigation of humans with induced marginal
biotin deficiency has shown a much greater reduction in
levels of SLC19A3 mRNA in blood leukocytes than of
mRNAs for 10 known biotin-related genes (Vlasova et
al. 2005). These findings implicate SLC19A3 in biotin
metabolism and indicate that it is a more sensitive in-
dicator of biotin deficiency than the known biotin car-
boxylases, holocarboxylase synthetase, biotinidase, and
the sodium-dependent multivitamin transporter.
In seeming contradiction with this hypothesis,
SLC19A3 has recently been reported to be a second thi-
amin transporter (Rajgopal et al. 2001), like SLC19A2.
These investigators used HeLa cells that were transiently
transfected with SLC19A3 cDNA to assess the transport
activity for radiolabeled thiamin, folic acid, and metho-
trexate, but they did not test biotin. To date, the genes
encoding the putative pyridoxine (vitamin B6) and niacin
transporters also have not been identified. An uptake
assay to reveal a novel transporter function should in-
clude those micronutrients to also test for the possibility
of multivitamin transport via the same protein. Interest-
ingly, Na-dependent multivitamin transporter, the in-
testinal biotin transporter, is also used by two other mi-
cronutrients, pantothenic acid and lipoate (Prasad et al.
1998, 1999; Wang et al. 1999). Additional work is re-
quired to establish whether SLC19A3 is capable of trans-
porting biotin in addition to thiamin or, alternatively,
whether the positive effect of biotin therapy in BBGD
acts indirectly to rescue the effects of altered SLC19A3
transport of thiamin or another micronutrient.
In either of the above circumstances, explaining the
brain-specific effects in patients with BBGD may require
a fuller delineation and understanding of the options
for biotin and thiamin transport, of the relative cellular
distributions of the various transporters, of the specific
requirements of different cells and tissues for these vi-
tamins, and of the specific roles of biotin in different
cells. Notably, global biotin deficiency produces many
symptoms not seen in patients with BBGD, such as dry
skin, seborrheic dermatitis, fungal infections, erythem-
atous periorifacial macular rashes, nausea, and ano-
rexia. The absence of these symptoms in patients with
BBGD suggests that sufficient biotin is available in all
regions except the brain. Moreover, the brain MRI find-
ings in patients with biotinidase deficiency and those
with multiple carboxylase deficiency are also different
from the findings observed in patients with BBGD, im-
plying that biotin may have other potential roles in the
striatum beyond that of cofactor for carboxylases (Mc-
Mahon 2002). Interestingly, several studies suggest that
biotin may be involved directly or indirectly in the reg-
ulation of gene expression (Rodriguez-Melendez and
Zempleni 2003), raising another option for the mech-
anism by which SLC19A3 mutation may lead to the
basal ganglia necrosis of BBGD.
As a result of the wider use of advanced brain imaging
technologies such as MRI and CT, bilateral striatal ne-
crosis has been recognized in a number of disorders
(Fujita et al. 1994; Okiyama et al. 1994; Sola Martinez
et al. 1994). Extrapyramidal symptoms are the main
clinical correlates of striatal necrosis and can be ob-
served in mitochondrial encephalopathies (Martin et al.
1988; Medina et al. 1990; Leuzzi et al. 1992; Thyaga-
rajan et al. 1995), glutaric acidemia type I, 3-methyl-
glutaconic academia (Gascon et al. 1994), Huntington
disease (Finch 1980; Buck et al. 1981), Wilson disease
(Sener 1993), and CNS infection (Larsen and Crisp
1996; Zambrino et al. 2000). Detailed clinical evidence
excluded those diagnoses in patients with BBGD who
were described elsewhere (Ozand et al. 1998). However,
since the description of BBGD, this pathology has been
described in patients with a novel disorder, infantile bi-
lateral striatal necrosis (IBSN), in which symmetric de-
generation of the caudate and putamen was observed.
Interestingly, three patients were reported to have mod-
erate response to biotin (Straussberg et al. 2002). In one
Israeli Bedouin kindred showing an autosomal recessive
inheritance pattern, linkage analysis refined the critical
candidate region on 19q13 (Basel-Vanagaite et al. 2004).
In view of the similarity of IBSN to BBGD, we specifically
tested the IBSN locus–flanking markers D19S596 and
D19S867, to examine the possible involvement of this
locus in BBGD. Linkage of BBGD to 19q13 was specif-
ically excluded, indicating that these similar disorders are
not allelic. However, careful comparison of these disor-
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ders and their degree of response to biotin may reveal
new information concerning the role that biotin plays in
the striatum. Similarly, the mechanism of striatal necrosis
in IBSN and BBGD may indicate that an assessment of
the potential participation of biotin metabolism in other
neurodegenerative disorders of the striatum, such as
Huntington disease, should be considered.
Although we identified the BBGD gene using Arab
kindreds, it is likely that this disorder exists in other
populations but that it may not have been recognized
because it has only recently been formally described.
Identification of mutations in the SLC19A3 gene will
help to differentiate and confirm the clinical diagnosis
of BBGD and will open an avenue for prenatal and pre-
symptomatic diagnosis. Early molecular diagnosis of
BBGD is particularly important to prevent basal ganglia
damage, since the progression of the pathology and of
the clinical course of symptoms can be prevented simply
by the administration of biotin. It is important to assess
whether patients with phenotypic similarilites to those
with BBGD are known within the neurogenetics com-
munity in the United States and elsewhere, since iden-
tification of such patients will permit their effective
treatment and will prevent unnecessary debilitation and
premature death.
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Web Resources
Accession numbers and URLs for data presented herein are
as follows:
BLAST, http://www.ncbi.nlm.nih.gov/blast/ (for BLASTX,
TBLASTN, and BLASTP)
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (for nine novel SNPs
in the 5′ UTR, alt3, alt6′, and alt7′ of SLC19A3 and
DKFZp547H025 [accession numbers 32476166–32476174])
Fondation Jean Dausset CEPH Web Server, http://www.cephb
.fr/ (for CEPH family genotypes used in map construction)
HMMTOP 2.0, http://www.enzim.hu/hmmtop/index.html
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GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for
DKFZp547H025 mRNA [accession number NM_020161])
NCBI Entrez Protein Database, http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?dbpprotein&cmdpsearch&termp (for
SLC19A3 [accession number NP_079519])
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for BBGD)
Primer3, http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www
.cgi
UCSC Genome Browser, http://genome.ucsc.edu/
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